Overview

• U.S. healthcare tech provider's Q4 revenue declined slightly from prior year

• GAAP net loss widened in Q4, but non-GAAP net income rose sharply

• Company revised prior financials errors in revenue and cost timing, deeming them "not material" to its consolidated 2023-2025 financial statements

Outlook

• TruBridge says it will focus on operational improvements and a targeted AI initiative in 2026

• Company is conducting a strategic review, considering alternatives including a sale or business combination

Result Drivers

• COST MANAGEMENT & OFFSHORING - Co said margin improvement was driven by cost management and execution of its offshoring strategy

• ORGANIZATIONAL CHANGES - Co said organizational changes have positioned it to drive improved customer satisfaction and results for shareholders

Company press release: ID:nBwwMg37a

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

• Wall Street's median 12-month price target for TruBridge Inc is $21.00, about 50% above its March 30 closing price of $14.00

• The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 11 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)